论文部分内容阅读
索他洛尔(Sotalol)是一种非选择性β-受体拮抗剂,它可延长心脏的复极化而不受其抗肾上腺能作用的支配(Ⅲ类抗心律失常特性).索他洛尔的这种抗心律失常作用看来主要是由Ⅲ类的特性所产生的,且比传统的β-阻断剂具有更广泛的抗心律失常作用.在控制发作性室上性心动过速和预激综合征的房颤或房补的心室效应方面,在房颤或房扑施行心脏电复律后维持窦律方面,以及在防止冠脉搭桥术后引发的室上性心动过速方面,索他洛尔均有疗效.在对非恶性和危及生命的室性心律失常,尤其对缺血性心脏病引起的室性心律失常的控制方面,本
Sotalol is a nonselective β-receptor antagonist that prolongs the heart’s repolarization independently of its anti-adrenergic properties (class III anti-arrhythmic properties) This anti-arrhythmic effect of Seoul appears to be mainly due to the properties of class III and has a broader anti-arrhythmic effect than conventional [beta] -blockers. In controlling episodic supraventricular tachycardia and Wolff-Parkinson’s syndrome atrial fibrillation or atrial fibrillation ventricular effects, atrial fibrillation or atrial flutter in the implementation of cardioversion to maintain sinus rhythm, and to prevent post-coronary bypass caused by supraventricular tachycardia, Sotalol are effective in non-malignant and life-threatening ventricular arrhythmias, especially in the control of ventricular arrhythmias caused by ischemic heart disease, the